Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: August 2008
-
By Christopher P. Singer — In a Notice published in the Federal Register (73 Fed. Reg. 47534) on Thursday, August 14, 2008, the U.S. Patent and Trademark Office announced that certain patent fee amounts are being adjusted to reflect fluctuations in the Consumer Price Index (CPI) for financial year 2009. The effective date…
-
By Kevin E. Noonan — The Subcommittee on Health of the House of Representatives’ Committee on Energy and Commerce recently solicited comments and information on so-called "follow-on biologics" (FOBs) from stakeholders and other interested parties. The Subcommittee on Health’s letter, signed by Subcommittee chairman Frank Pallone, Jr. (D-NJ, 6th Dist.) and ranking member…
-
By Donald Zuhn — Earlier this year, we reported on the campaign undertaken by Insmed Inc., a biopharmaceutical company based in Richmond, VA, to raise national awareness about the importance of establishing a regulatory pathway in the U.S. for follow-on biologics. As part of that campaign, Insmed commissioned an economic study of the…
-
By Donald Zuhn — Ulysses Pharmaceuticals announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,410,974, which is directed to a class of compounds that exhibit antibiotic activity against a wide spectrum of microorganisms, including organisms that are resistant to multiple antibiotic families (the so-called "superbugs"). According to…
-
By Donald Zuhn — Last Tuesday, CongressDaily reported that Senate Judiciary Chairman Patrick Leahy (D-VT) (at right) and ranking member Arlen Specter (R-PA) have indicated that patent reform will be a top priority for the new session. Coalition for Patent Fairness lobbyist Steve Elmendorf told the publication that he expects to begin working…
-
Last week, Patent Docs posted an article by Kevin Noonan (see "Once Again, The New Yorker Gets It Wrong on Patents") regarding "The Permission Problem," an article by James Surowiecki that appears in the August 11th edition of The New Yorker. Over the weekend, Mr. Surowiecki and Dr. Noonan engaged in an interesting and spirited…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Sepracor Inc. et al. v. Barr Pharmaceuticals, Inc. et al.3:08-cv-03920; filed August 4, 2008 in the District Court of New Jersey Infringement…
-
August 11-12, 2008 – Advanced Patent Prosecution Workshop 2008: Claim Drafting & Amendment Writing (Practising Law Institute) – San Francisco, CA August 10-15, 2008 – Advanced Courses (Patent Resources Group) – Washington, DC September 11, 2008 – Developments in Pharmaceutical and Biotech Patent Law (Practising Law Institute) – New York, NY September 11-12, 2008 –…
-
The Center for Business Intelligence (CBI) will be holding its Pharmaceutical Congress on Paragraph IV Disputes on October 15-16 in Philadelphia, PA. The conference will cover important issues for both brand and generic companies during two days of presentations and panel discussions on litigation strategies, statutory guidelines, current cases, and their landmark decisions. Topics to…
-
By Donald Zuhn and Christopher P. Singer — In a Notice published in the Federal Register on August 7, 2008 ("Clarification of Patent Regulations Currently in Effect, and Revision in Applicability Date of Provisions Relating to Patent Applications Containing Patentably Indistinct Claims," 73 Fed. Reg. 45999), the U.S. Patent and Trademark Office "clarified"…
Patent Docs 